Chris Labaki takes us through his study evaluating temporal changes in the screening, diagnosis, and surgical treatment of genitourinary malignancies during the first year of the COVID-19 pandemic.

Editorial board member Axel Merseburger discusses the clinical implications of key genitourinary cancer abstracts presented at the 2021 ASCO Annual Meeting, including the KEYNOTE-564 and VISION trials, as well as brain metastases data from CheckMate 920 and updates on several enfortumab vedotin studies.

Genitourinary oncologists Cora Sternberg and Axel Merseburger share their experience of managing cancer patients during the COVID-19 pandemic, comparing perspectives from a US and German stand point.

Axel Merseburger takes us through his top picks of the genitourinary cancer research reported at the ESMO Congress 2019, including updates on the TITAN and STAMPEDE prostate cancer trials, the SORCE trial in renal cell carcinoma, and the investigation of first-line enfortumab vedotin in bladder cancer (5:33).

Axel Merseburger takes us through his picks of the genitourinary cancers track of the virtual 2020 ASCO Annual Meeting, including the JAVELIN Bladder 100 and KEYNOTE-426 trials (10:28).

There's a new home for news and congress coverage! Catch up on all the top stories and latest evidence in oncology research with our ESMO congress hub page.  Learn more »

Men with localized prostate cancer and high-risk biochemical recurrence benefit from treatment with enzalutamide, either alongside leuprolide or alone.

Patients with oligometastatic castration-resistant prostate cancer benefit from the addition of stereotactic body radiotherapy to first-line abiraterone acetate plus prednisone.

The combination of pembrolizumab and lenvatinib has durable antitumor activity and promising survival outcomes in treatment-naïve patients with advanced non-clear-cell renal cell carcinoma, say the KEYNOTE-B61 investigators.

Adding talazoparib to enzalutamide significantly improves the outcomes of untreated patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair mutation status, shows the TALAPRO-2 trial.

Pregnancy-associated cancers may be linked to an elevated 5-year mortality risk, but the risk varies by tumor site and time of diagnosis, suggests a population-based cohort study.

Nik-Ahd and colleagues continue: “Lower rates may stem from less PSA screening owing to barriers including lack of prostate cancer risk awareness or stigma, the suppressive effects of estrogen on prostate cancer development, or prostate cancers being missed in transgender women because of misinterpretation of ‘normal’ PSA levels among those receiving gender-affirming hormone therapies.”

An update presented at the 2019 ASCO Genitourinary Cancers Symposium for 249 patients after a median 2.7 years gave an ORR of 16.5%, a median duration of response (DOR) of 20.5 months, and median PFS and OS of 1.6 and 7.0 months, respectively.

Find out more about the evidence-based recommendations here

Older individuals with a history of cancer, especially those with a more recent diagnosis, have a higher risk for frailty-related bone fractures than their cancer-free counterparts, suggests a large longitudinal study.

Details of this Clinical Practice Guideline available here

De-escalating chemoradiotherapy may be a feasible strategy for some patients with stage IIA or IIB classic seminoma, suggest the SAKK 01/10 trial investigators.